

Copy of MD7512 Clinical Presentation & Management of Diabetes: Complications & Cardiovascular Disease

View Online



Clinical Presentation & Management of Diabetes:
Complications & Cardiovascular Disease

Abdul-Ghani, M., DeFronzo, R. A., Del Prato, S., Chilton, R., Singh, R., & Ryder, R. E. J. (2017). Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived? *Diabetes Care*, 40(7), 813–820. <https://doi.org/10.2337/dc16-2736>

Adamsson Eryd, S., Svensson, A.-M., Franzén, S., Eliasson, B., Nilsson, P. M., & Gudbjörnsdóttir, S. (2017). Risk of future microvascular and macrovascular disease in people with Type 1 diabetes of very long duration: a national study with 10-year follow-up. *Diabetic Medicine*, 34(3), 411–418. <https://doi.org/10.1111/dme.13266>

Andersson, D. P., Trolle Lagerros, Y., Grotta, A., Bellocco, R., Lehtihet, M., & Holzmann, M. J. (2017). Association between treatment for erectile dysfunction and death or cardiovascular outcomes after myocardial infarction. *Heart*. <https://doi.org/10.1136/heartjnl-2016-310746>

Assessing the relationship between admission glucose levels, subsequent length of hospital stay, readmission and mortality. (n.d.). Prime. https://www.unboundmedicine.com/medline/citation/22586788/Assessing_the_relationship_between_admission_glucose_levels_subsequent_length_of_hospital_stay_readmission_and_mortality_

Atkinson, M. A., Eisenbarth, G. S., & Michels, A. W. (2014). Type 1 diabetes. *The Lancet*, 383(9911), 69–82. [https://doi.org/10.1016/S0140-6736\(13\)60591-7](https://doi.org/10.1016/S0140-6736(13)60591-7)

Azmi, S., Ferdousi, M., Alam, U., Petropoulos, I. N., Ponirakis, G., Marshall, A., Asghar, O., Fadavi, H., Jones, W., Tavakoli, M., Boulton, A. J. M., Jeziorska, M., Soran, H., Efron, N., & Malik, R. A. (2017). Small-fibre neuropathy in men with type 1 diabetes and erectile dysfunction: a cross-sectional study. *Diabetologia*. <https://doi.org/10.1007/s00125-017-4245-z>

Bangalore, S., Kumar, S., Lobach, I., & Messerli, F. H. (2011). Blood Pressure Targets in Subjects With Type 2 Diabetes Mellitus/Impaired Fasting Glucose: Observations From Traditional and Bayesian Random-Effects Meta-Analyses of Randomized Trials. *Circulation*, 123(24), 2799–2810. <https://doi.org/10.1161/CIRCULATIONAHA.110.016337>

Barzilay, J. I., Davis, B. R., Pressel, S. L., Cutler, J. A., Einhorn, P. T., Black, H. R., Cushman, W. C., Ford, C. E., Margolis, K. L., Moloo, J., Oparil, S., Piller, L. B., Simmons, D. L., Sweeney, M. E., Whelton, P. K., Wong, N. D., & Wright, J. T. (2012). Long-Term Effects of Incident Diabetes Mellitus on Cardiovascular Outcomes in People Treated for Hypertension: The ALLHAT Diabetes Extension Study. *Circulation: Cardiovascular Quality and Outcomes*, 5(2),

153-162. <https://doi.org/10.1161/CIRCOUTCOMES.111.962522>

Bianchi, C., Miccoli, R., & Del Prato, S. (2013a). Hyperglycemia and Vascular Metabolic Memory: Truth or Fiction? *Current Diabetes Reports*, 13(3), 403-410. <https://doi.org/10.1007/s11892-013-0371-2>

Bianchi, C., Miccoli, R., & Del Prato, S. (2013b). Hyperglycemia and Vascular Metabolic Memory: Truth or Fiction? *Current Diabetes Reports*, 13(3), 403-410. <https://doi.org/10.1007/s11892-013-0371-2>

Black, J. A., Sharp, S. J., Wareham, N. J., Sandbaek, A., Rutten, G. E., Lauritzen, T., Khunti, K., Davies, M. J., Borch-Johnsen, K., Griffin, S. J., & Simmons, R. K. (2014). Change in cardiovascular risk factors following early diagnosis of type 2 diabetes: a cohort analysis of a cluster-randomised trial. *British Journal of General Practice*, 64(621), e208-e216. <https://doi.org/10.3399/bjgp14X677833>

Boulton, A. J., Jeffcoate, W. J., Jones, T. L., & Ulbrecht, J. S. (2009). International collaborative research on Charcot's disease - 2009. *The Lancet*, 373(9658), 105-106. [https://doi.org/10.1016/S0140-6736\(09\)60019-2](https://doi.org/10.1016/S0140-6736(09)60019-2)

Boussageon, R., Bejan-Angoulvant, T., Saadatian-Elahi, M., Lafont, S., Bergeonneau, C., Kassai, B., Erpeldinger, S., Wright, J. M., Gueyffier, F., & Cornu, C. (2011). Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. *BMJ*, 343(jul26 1), d4169-d4169. <https://doi.org/10.1136/bmj.d4169>

Braffett, B. H., Wessells, H., & Sarma, A. V. (2016). Urogenital Autonomic Dysfunction in Diabetes. *Current Diabetes Reports*, 16(12). <https://doi.org/10.1007/s11892-016-0824-5>

Çakici, N., Fakkal, T. M., van Neck, J. W., Verhagen, A. P., & Coert, J. H. (2016a). Systematic review of treatments for diabetic peripheral neuropathy. *Diabetic Medicine*, 33(11), 1466-1476. <https://doi.org/10.1111/dme.13083>

Çakici, N., Fakkal, T. M., van Neck, J. W., Verhagen, A. P., & Coert, J. H. (2016b). Systematic review of treatments for diabetic peripheral neuropathy. *Diabetic Medicine*, 33(11), 1466-1476. <https://doi.org/10.1111/dme.13083>

Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes - ClinicalKey. (n.d.). <https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S0140673614607947>

Cefalu, W. T., Rosenstock, J., LeRoith, D., Blonde, L., & Riddle, M. C. (2016). Getting to the "Heart" of the Matter on Diabetic Cardiovascular Disease: "Thanks for the Memory". *Diabetes Care*, 39(5), 664-667. <https://doi.org/10.2337/dc16-0405>

Chatterjee, S., Khunti, K., & Davies, M. J. (2017). Type 2 diabetes. *The Lancet*. [https://doi.org/10.1016/S0140-6736\(17\)30058-2](https://doi.org/10.1016/S0140-6736(17)30058-2)

Cheung, N., Mitchell, P., & Wong, T. Y. (2010). Diabetic retinopathy. *The Lancet*, 376(9735), 124-136. [https://doi.org/10.1016/S0140-6736\(09\)62124-3](https://doi.org/10.1016/S0140-6736(09)62124-3)

- Chloe L. Edridge. (2015). Prevalence and Incidence of Hypoglycaemia in 532,542 People with Type 2 Diabetes on Oral Therapies and Insulin: A Systematic Review and Meta-Analysis of Population Based Studies. *PLoS ONE*, 10(6). <https://doi.org/doi:10.1371/journal.pone.0126427>
- Clokie, M., Greenway, A. L., Harding, K., Jones, N. J., Vedhara, K., Game, F., & Dhatariya, K. K. (2017). New horizons in the understanding of the causes and management of diabetic foot disease: report from the 2017 Diabetes UK Annual Professional Conference Symposium. *Diabetic Medicine*, 34(3), 305–315. <https://doi.org/10.1111/dme.13313>
- Dahlöf, B., Sever, P. S., Poulter, N. R., Wedel, H., Beevers, D. G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., Mehlsen, J., Nieminen, M., O'Brien, E., & Östergren, J. (2005). Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. *The Lancet*, 366(9489), 895–906. [https://doi.org/10.1016/S0140-6736\(05\)67185-1](https://doi.org/10.1016/S0140-6736(05)67185-1)
- Dana Dabelea. (n.d.). Association of Type 1 Diabetes vs Type 2 Diabetes Diagnosed During Childhood and Adolescence With Complications During Teenage Years and Young Adulthood. *JAMA*, 317(8), 825–835. <https://doi.org/10.1001/jama.2017.0686>
- Denig, P., Schuling, J., Haaijer-Ruskamp, F., & Voorham, J. (2014). Effects of a patient oriented decision aid for prioritising treatment goals in diabetes: pragmatic randomised controlled trial. *BMJ*, 349(sep25 6), g5651–g5651. <https://doi.org/10.1136/bmj.g5651>
- Dhatariya, K. K., & Vellanki, P. (2017). Treatment of Diabetic Ketoacidosis (DKA)/Hyperglycemic Hyperosmolar State (HHS): Novel Advances in the Management of Hyperglycemic Crises (UK Versus USA). *Current Diabetes Reports*, 17(5). <https://doi.org/10.1007/s11892-017-0857-4>
- Dhatariya, K., Levy, N., Kilvert, A., Watson, B., Cousins, D., Flanagan, D., Hilton, L., Jairam, C., Leyden, K., Lipp, A., Lobo, D., Sinclair-Hammersley, M., & Rayman, G. (2012). NHS Diabetes guideline for the perioperative management of the adult patient with diabetes. *Diabetic Medicine*, 29(4), 420–433. <https://doi.org/10.1111/j.1464-5491.2012.03582.x>
- Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. (2010). *The Lancet*, 375(9733), 2215–2222. [https://doi.org/10.1016/S0140-6736\(10\)60484-9](https://doi.org/10.1016/S0140-6736(10)60484-9)
- Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death. (2011). *New England Journal of Medicine*, 364(9), 829–841. <https://doi.org/10.1056/NEJMoa1008862>
- Diabetes Mellitus Type 2: A Driving Force for Urological Complications - ClinicalKey. (n.d.-a). <https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S1043276016000321>
- Diabetes Mellitus Type 2: A Driving Force for Urological Complications - ClinicalKey. (n.d.-b). <https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S1043276016000321>

00321

Diabetic foot problems: prevention and management | Guidance and guidelines | NICE. (n.d.). <https://www.nice.org.uk/guidance/ng19>

Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., Warren, S. R., Goldman, S., McCarren, M., Vitek, M. E., Henderson, W. G., & Huang, G. D. (2009). Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes. *New England Journal of Medicine*, 360(2), 129–139. <https://doi.org/10.1056/NEJMoa0808431>

Dwamena, F., Holmes-Rovner, M., Gaulden, C. M., Jorgenson, S., Sadigh, G., Sikorskii, A., Lewin, S., Smith, R. C., Coffey, J., Olomu, A., & Beasley, M. (1996). Interventions for providers to promote a patient-centred approach in clinical consultations. In *Cochrane Database of Systematic Reviews*. John Wiley & Sons, Ltd. <https://doi.org/10.1002/14651858.CD003267.pub2>

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). (1998). *The Lancet*, 352(9131), 854–865. [https://doi.org/10.1016/S0140-6736\(98\)07037-8](https://doi.org/10.1016/S0140-6736(98)07037-8)

Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus. (2010). *New England Journal of Medicine*, 362(17), 1563–1574. <https://doi.org/10.1056/NEJMoa1001282>

Effects of Different Blood Pressure-Lowering Regimens on Major Cardiovascular Events in Individuals With and Without Diabetes Mellitus. (2005). *Archives of Internal Medicine*, 165(12). <https://doi.org/10.1001/archinte.165.12.1410>

Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus. (2010a). *New England Journal of Medicine*, 362(17), 1575–1585. <https://doi.org/10.1056/NEJMoa1001286>

Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus. (2010b). *New England Journal of Medicine*, 362(17), 1575–1585. <https://doi.org/10.1056/NEJMoa1001286>

Effects of Intensive Glucose Lowering in Type 2 Diabetes. (2008). *New England Journal of Medicine*, 358(24), 2545–2559. <https://doi.org/10.1056/NEJMoa0802743>

Effects of reducing blood pressure on renal outcomes in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME - ClinicalKey. (n.d.). <https://www.clinicalkey.com/#!/content/journal/1-s2.0-S1262363617300022>

Ele Ferrannini. (2015). Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. *European Heart Journal*, 36(34), 2288–2296. <http://eurheartj.oxfordjournals.org/content/36/34/2288>

Elliott, W. J., & Meyer, P. M. (2007). Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. *The Lancet*, 369(9557), 201–207. [https://doi.org/10.1016/S0140-6736\(07\)60108-1](https://doi.org/10.1016/S0140-6736(07)60108-1)

- Ferrannini, E., & Cushman, W. C. (2012). Diabetes and hypertension: the bad companions. *The Lancet*, 380(9841), 601–610. [https://doi.org/10.1016/S0140-6736\(12\)60987-8](https://doi.org/10.1016/S0140-6736(12)60987-8)
- Filippatos, T., Tsimihodimos, V., Pappa, E., & Elisaf, M. (2017). Pathophysiology of diabetic dyslipidaemia. *Current Vascular Pharmacology*, 15(999), 1–1.
- Fisher, L., Gonzalez, J. S., & Polonsky, W. H. (2014). The confusing tale of depression and distress in patients with diabetes: a call for greater clarity and precision. *Diabetic Medicine*, 31(7), 764–772. <https://doi.org/10.1111/dme.12428>
- Foresta, C., Ferlin, A., Lenzi, A., & Montorsi, P. (2017). The great opportunity of the andrological patient: cardiovascular and metabolic risk assessment and prevention. *Andrology*. <https://doi.org/10.1111/andr.12342>
- Fox, C. S., Golden, S. H., Anderson, C., Bray, G. A., Burke, L. E., de Boer, I. H., Deedwania, P., Eckel, R. H., Ershow, A. G., Fradkin, J., Inzucchi, S. E., Kosiborod, M., Nelson, R. G., Patel, M. J., Pignone, M., Quinn, L., Schauer, P. R., Selvin, E., & Vafiadis, D. K. (2015). Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association. *Diabetes Care*, 38(9), 1777–1803. <https://doi.org/10.2337/dci15-0012>
- Frequency of Evidence-Based Screening for Retinopathy in Type 1 Diabetes. (2017). *New England Journal of Medicine*, 376(16), 1507–1516. <https://doi.org/10.1056/NEJMoa1612836>
- Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2008). Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes. *New England Journal of Medicine*, 358(6), 580–591. <https://doi.org/10.1056/NEJMoa0706245>
- Gæde, P., Oellgaard, J., Carstensen, B., Rossing, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2016). Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. *Diabetologia*, 59(11), 2298–2307. <https://doi.org/10.1007/s00125-016-4065-6>
- Game, F. (2016). Classification of diabetic foot ulcers. *Diabetes/Metabolism Research and Reviews*, 32, 186–194. <https://doi.org/10.1002/dmrr.2746>
- Giorgino, F., Home, P. D., & Tuomilehto, J. (2016). Glucose Control and Vascular Outcomes in Type 2 Diabetes: Is the Picture Clear? *Diabetes Care*, 39(Supplement 2), S187–S195. <https://doi.org/10.2337/dcS15-3023>
- Giovanni Corona. (2016). Sexual Dysfunction in Type 2 Diabetes at Diagnosis: Progression over Time and Drug and Non-Drug Correlated Factors. *PLoS ONE*, 11(10). <https://doi.org/doi:10.1371/journal.pone.0157915>
- Hayward, R. A., Reaven, P. D., Wiitala, W. L., Bahn, G. D., Reda, D. J., Ge, L., McCarren, M., Duckworth, W. C., & Emanuele, N. V. (2015a). Follow-up of Glycemic Control and Cardiovascular Outcomes in Type 2 Diabetes. *New England Journal of Medicine*, 372(23), 2197–2206. <https://doi.org/10.1056/NEJMoa1414266>

Hayward, R. A., Reaven, P. D., Wiitala, W. L., Bahn, G. D., Reda, D. J., Ge, L., McCarren, M., Duckworth, W. C., & Emanuele, N. V. (2015b). Follow-up of Glycemic Control and Cardiovascular Outcomes in Type 2 Diabetes. *New England Journal of Medicine*, 372(23), 2197–2206. <https://doi.org/10.1056/NEJMoa1414266>

Holman, R. R., Bethel, M. A., Mentz, R. J., Thompson, V. P., Lokhnygina, Y., Buse, J. B., Chan, J. C., Choi, J., Gustavson, S. M., Iqbal, N., Maggioni, A. P., Marso, S. P., Öhman, P., Pagidipati, N. J., Poulter, N., Ramachandran, A., Zinman, B., & Hernandez, A. F. (2017). Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. *New England Journal of Medicine*, 377(13), 1228–1239. <https://doi.org/10.1056/NEJMoa1612917>

Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008). 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes. *New England Journal of Medicine*, 359(15), 1577–1589. <https://doi.org/10.1056/NEJMoa0806470>

Holt, R. I. G. (2010). *Textbook of diabetes* (4th ed). Wiley-Blackwell.
<http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077>

Holt, R. I. G. (2017). Understanding of the causes and management of diabetic foot disease. *Diabetic Medicine*, 34(3), 303–304. <https://doi.org/10.1111/dme.13319>

Holt, R. I. G., Cockram, C., Flyvbjerg, A., & Goldstein, B. J. (2016). *Textbook of Diabetes* (5th ed). John Wiley & Sons, Incorporated.
<http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056>

Holt, R. I. G., Cockram, C. S., Flyvbjerg, A., & Goldstein, B. J. (Eds.). (2017). *Textbook of diabetes* (Fifth edition). Wiley Blackwell.
<http://ezproxy.lib.le.ac.uk/login?url=http://ebookcentral.proquest.com.ezproxy3.lib.le.ac.uk/lib/leicester/detail.action?docID=4769056>

Hotaling, J. M., Sarma, A. V., Patel, D. P., Braffett, B. H., Cleary, P. A., Feldman, E., Herman, W. H., Martin, C. L., Jacobson, A. M., Wessells, H., & Pop-Busui, R. (2016a). Cardiovascular Autonomic Neuropathy, Sexual Dysfunction, and Urinary Incontinence in Women With Type 1 Diabetes. *Diabetes Care*, 39(9), 1587–1593. <https://doi.org/10.2337/dc16-0059>

Hotaling, J. M., Sarma, A. V., Patel, D. P., Braffett, B. H., Cleary, P. A., Feldman, E., Herman, W. H., Martin, C. L., Jacobson, A. M., Wessells, H., & Pop-Busui, R. (2016b). Cardiovascular Autonomic Neuropathy, Sexual Dysfunction, and Urinary Incontinence in Women With Type 1 Diabetes. *Diabetes Care*, 39(9), 1587–1593. <https://doi.org/10.2337/dc16-0059>

Hypertension: Clinical Management of Primary Hypertension in Adults | NICE guideline 127. August 2011. (n.d.). <http://www.nice.org.uk/guidance/cg127>

Ian Blumer, MD, FRCPC1, 2, Maureen Clement, MD, CCFP3, . (n.d.). Type 2 Diabetes, Hypoglycemia, and Basal Insulins: Ongoing Challenges. *Type 2 Diabetes, Hypoglycemia, and Basal Insulins: Ongoing Challenges*.
<http://www.sciencedirect.com.ezproxy4.lib.le.ac.uk/science/article/pii/S0149291816307792>

Integration of recent evidence into management of patients with atherosclerotic

cardiovascular disease and type 2 diabetes - ClinicalKey. (n.d.).

<https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858717300335>

Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. (2008). *New England Journal of Medicine*, 358(24), 2560–2572.

<https://doi.org/10.1056/NEJMoa0802987>

Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes. (2005). *New England Journal of Medicine*, 353(25), 2643–2653.

<https://doi.org/10.1056/NEJMoa052187>

Intensive systolic blood pressure control and incident chronic kidney disease in people with and without diabetes mellitus: secondary analyses of two randomised controlled trials- ClinicalKey. (n.d.).

<https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858718300998>

International Textbook of Diabetes Mellitus (4th ed.). (2015). John Wiley & Sons, Incorporated.

<http://ebookcentral.proquest.com.ezproxy3.lib.le.ac.uk/lib/leicester/detail.action?docID=1895437>

Jhamb, S., Vangaveti, V. N., & Malabu, U. H. (2016). Genetic and molecular basis of diabetic foot ulcers: Clinical review. *Journal of Tissue Viability*, 25(4), 229–236.

<https://doi.org/10.1016/j.jtv.2016.06.005>

Jin, D., Xu, Y., Geng, D., & Yan, T. (2010). Effect of transcutaneous electrical nerve stimulation on symptomatic diabetic peripheral neuropathy: A meta-analysis of randomized controlled trials. *Diabetes Research and Clinical Practice*, 89(1), 10–15.

<https://doi.org/10.1016/j.diabres.2010.03.021>

Johal, S., Jackson-Spence, F., Gillott, H., Tahir, S., Mytton, J., Evison, F., Stephenson, B., Nath, J., & Sharif, A. (2017). Pre-existing diabetes is a risk factor for increased rates of cellular rejection after kidney transplantation: an observational cohort study. *Diabetic Medicine*. <https://doi.org/10.1111/dme.13383>

Kaul, S. (2017). Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials. *Diabetes Care*, 40(7), 821–831. <https://doi.org/10.2337/dc17-0291>

Khunti, K., Davies, M., Majeed, A., Thorsted, B. L., Wolden, M. L., & Paul, S. K. (2015a). Hypoglycemia and Risk of Cardiovascular Disease and All-Cause Mortality in Insulin-Treated People With Type 1 and Type 2 Diabetes: A Cohort Study. *Diabetes Care*, 38(2), 316–322. <https://doi.org/10.2337/dc14-0920>

Khunti, K., Davies, M., Majeed, A., Thorsted, B. L., Wolden, M. L., & Paul, S. K. (2015b). Hypoglycemia and Risk of Cardiovascular Disease and All-Cause Mortality in Insulin-Treated People With Type 1 and Type 2 Diabetes: A Cohort Study. *Diabetes Care*, 38(2), 316–322. <https://doi.org/10.2337/dc14-0920>

Khunti, K., Wolden, M. L., Thorsted, B. L., Andersen, M., & Davies, M. J. (2013). Clinical Inertia in People With Type 2 Diabetes: A retrospective cohort study of more than 80,000 people. *Diabetes Care*, 36(11), 3411–3417. <https://doi.org/10.2337/dc13-0331>

Koye, D. N., Shaw, J. E., Reid, C. M., Atkins, R. C., Reutens, A. T., & Magliano, D. J. (2017). Incidence of chronic kidney disease among people with diabetes: a systematic review of observational studies. *Diabetic Medicine*. <https://doi.org/10.1111/dme.13324>

Kunutsor, S. K., Seidu, S., & Khunti, K. (2017). Aspirin for primary prevention of cardiovascular and all-cause mortality events in diabetes: updated meta-analysis of randomized controlled trials. *Diabetic Medicine*, 34(3), 316–327. <https://doi.org/10.1111/dme.13133>

Liew, G., Mitchell, P., & Wong, T. Y. (2009). Systemic management of diabetic retinopathy. *BMJ*, 338(feb12 1), b441–b441. <https://doi.org/10.1136/bmj.b441>

Lindholm, L. H., Ibsen, H., Dahlöf, B., Devereux, R. B., Beevers, G., de Faire, U., Fyhrquist, F., Julius, S., Kjeldsen, S. E., Kristiansson, K., Lederballe-Pedersen, O., Nieminen, M. S., Omvik, P., Oparil, S., Wedel, H., Aurup, P., Edelman, J., & Snapinn, S. (2002). Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. *The Lancet*, 359(9311), 1004–1010. [https://doi.org/10.1016/S0140-6736\(02\)08090-X](https://doi.org/10.1016/S0140-6736(02)08090-X)

Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data - ClinicalKey. (n.d.). <https://www-clinicalkey-com.ezproxy4.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858716000036>

Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes. (2011). *New England Journal of Medicine*, 364(9), 818–828. <https://doi.org/10.1056/NEJMoa1006524>

Macrovascular disease and risk factors in youth with type 1 diabetes: time to be more attentive to treatment?- ClinicalKey. (n.d.-a). <https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858718300354>

Macrovascular disease and risk factors in youth with type 1 diabetes: time to be more attentive to treatment?- ClinicalKey. (n.d.-b). <https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858718300354>

Macrovascular disease and risk factors in youth with type 1 diabetes: time to be more attentive to treatment?- ClinicalKey. (n.d.-c). <https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858718300354>

Malavige, L. S., Wijesekara, P., Ranasinghe, P., & Levy, J. C. (2015). The association between physical activity and sexual dysfunction in patients with diabetes mellitus of European and South Asian origin: The Oxford Sexual Dysfunction Study. *European Journal*

of Medical Research, 20(1). <https://doi.org/10.1186/s40001-015-0186-5>

Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., Steinberg, W. M., Stockner, M., Zinman, B., Bergenstal, R. M., & Buse, J. B. (2016). Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. *New England Journal of Medicine*, 375(4), 311–322. <https://doi.org/10.1056/NEJMoa1603827>

Matheus, A. S. de M., Tannus, L. R. M., Cobas, R. A., Palma, C. C. S., Negrato, C. A., & Gomes, M. de B. (2013). Impact of Diabetes on Cardiovascular Disease: An Update. *International Journal of Hypertension*, 2013, 1–15. <https://doi.org/10.1155/2013/653789>

Mayer-Davis, E. J., Lawrence, J. M., Dabelea, D., Divers, J., Isom, S., Dolan, L., Imperatore, G., Linder, B., Marcovina, S., Pettitt, D. J., Pihoker, C., Saydah, S., & Wagenknecht, L. (2017). Incidence Trends of Type 1 and Type 2 Diabetes among Youths, 2002–2012. *New England Journal of Medicine*, 376(15), 1419–1429. <https://doi.org/10.1056/NEJMoa1610187>

Melanie Davies. (2016). The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies. *Clinical Pharmacology : Advances and Applications*, 8. <https://doi.org/doi:10.2147/CPAA.S82008>

Micha, R., Peñalvo, J. L., Cudhea, F., Imamura, F., Rehm, C. D., & Mozaffarian, D. (2017). Association Between Dietary Factors and Mortality From Heart Disease, Stroke, and Type 2 Diabetes in the United States. *JAMA*, 317(9). <https://doi.org/10.1001/jama.2017.0947>

Microvascular Complications and Foot Care. (2017). *Diabetes Care*, 40(Supplement 1), S88–S98. <https://doi.org/10.2337/dc17-S013>

Miller, M. E., Bonds, D. E., Gerstein, H. C., Seaquist, E. R., Bergenstal, R. M., Calles-Escandon, J., Childress, R. D., Craven, T. E., Cuddihy, R. M., Dailey, G., Feinglos, M. N., Ismail-Beigi, F., Largay, J. F., O'Connor, P. J., Paul, T., Savage, P. J., Schubart, U. K., Sood, A., & Genuth, S. (2010). The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. *BMJ*, 340(jan08 1), b5444–b5444. <https://doi.org/10.1136/bmj.b5444>

Minimizing Hypoglycemia in Diabetes: Table 1. (2015). *Diabetes Care*, 38(8), 1583–1591. <https://doi.org/10.2337/dc15-0279>

Moreton, R. B. R., Stratton, I. M., Chave, S. J., Lipinski, H., & Scanlon, P. H. (2017). Factors determining uptake of diabetic retinopathy screening in Oxfordshire. *Diabetic Medicine*, 34(7), 993–999. <https://doi.org/10.1111/dme.13350>

Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes. (2017). *New England Journal of Medicine*, 377(3), 300–301. <https://doi.org/10.1056/NEJMc1706292>

Navaneethan, S. D., Schold, J. D., Jolly, S. E., Arrigain, S., Winkelmayr, W. C., & Nally, J. V. (2017). Diabetes Control and the Risks of ESRD and Mortality in Patients With CKD. *American Journal of Kidney Diseases*. <https://doi.org/10.1053/j.ajkd.2016.11.018>

Nicolucci, A., & Standl, E. (2011). Antiplatelet Therapy for Every Diabetic Person? *Diabetes Care*, 34(Supplement_2), S150–S154. <https://doi.org/10.2337/dc11-s210>

Older antidiabetic drugs | *The British Journal of Cardiology*. (n.d.).
<https://bjcardio.co.uk/2018/03/older-antidiabetic-drugs/>

Omland, T., Randby, A., Hrubos-Strøm, H., Røsjø, H., & Einvik, G. (2016). Relation of Erectile Dysfunction to Subclinical Myocardial Injury. *The American Journal of Cardiology*, 118(12), 1821–1825. <https://doi.org/10.1016/j.amjcard.2016.08.070>

Orchard, T. J., Nathan, D. M., Zinman, B., Cleary, P., Brillon, D., Backlund, J.-Y. C., & Lachin, J. M. (2015). Association Between 7 Years of Intensive Treatment of Type 1 Diabetes and Long-term Mortality. *JAMA*, 313(1). <https://doi.org/10.1001/jama.2014.16107>

P Naidoo. (2015). Lower limb complications of diabetes mellitus: a comprehensive review with clinicopathological insights from a dedicated high-risk diabetic foot multidisciplinary team. *The British Journal of Radiology*, 88(1053). <https://doi.org/doi:10.1259/bjr.20150135>

Paul, S. K., Klein, K., Thorsted, B. L., Wolden, M. L., & Khunti, K. (2015). Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. *Cardiovascular Diabetology*, 14(1). <https://doi.org/10.1186/s12933-015-0260-x>

Personalised blood pressure ranges in type 2 diabetes?- *ClinicalKey*. (n.d.-a).
<https://www.clinicalkey.com/#!/content/journal/1-s2.0-S2213858718300020>

Personalised blood pressure ranges in type 2 diabetes?- *ClinicalKey*. (n.d.-b).
<https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858718300020>

Personalised treatment targets in type 2 diabetes patients: The Dutch approach - *ClinicalKey*. (n.d.).
<https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S1751991816300626>

Pickering, R. J., Rosado, C. J., Sharma, A., Buksh, S., Tate, M., & de Haan, J. B. (2018). Recent novel approaches to limit oxidative stress and inflammation in diabetic complications. *Clinical & Translational Immunology*, 7(4). <https://doi.org/10.1002/cti2.1016>

Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M.-T., Corrà, U., Cosyns, B., Deaton, C., Graham, I., Hall, M. S., Hobbs, F. D. R., Løchen, M.-L., Löllgen, H., Marques-Vidal, P., Perk, J., Prescott, E., Redon, J., ... Verschuren, W. M. M. (2016). 2016 European Guidelines on cardiovascular disease prevention in clinical practice. *Atherosclerosis*, 252, 207–274.
<https://doi.org/10.1016/j.atherosclerosis.2016.05.037>

Proceedings of the 5th International DAWN Summit 2014: Acting together to make person-centred diabetes care a reality - *ClinicalKey*. (n.d.).
<https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S0168822715001862>

Rawshani, A., Rawshani, A., Franzén, S., Eliasson, B., Svensson, A.-M., Miftaraj, M., McGuire, D. K., Sattar, N., Rosengren, A., & Gudbjörnsdottir, S. (2017a). Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes. *New England Journal of Medicine*, 376(15), 1407–1418. <https://doi.org/10.1056/NEJMoa1608664>

Rawshani, A., Rawshani, A., Franzén, S., Eliasson, B., Svensson, A.-M., Miftaraj, M., McGuire, D. K., Sattar, N., Rosengren, A., & Gudbjörnsdottir, S. (2017b). Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes. *New England Journal of Medicine*, 376(15), 1407–1418. <https://doi.org/10.1056/NEJMoa1608664>

Ray, K. K., Seshasai, S. R. K., Wijesuriya, S., Sivakumaran, R., Nethercott, S., Preiss, D., Erqou, S., & Sattar, N. (2009). Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. *The Lancet*, 373(9677), 1765–1772. [https://doi.org/10.1016/S0140-6736\(09\)60697-8](https://doi.org/10.1016/S0140-6736(09)60697-8)

Richard W. Nesto. (2008). LDL cholesterol lowering in type 2 diabetes: what is the optimum approach? *Clinical Diabetes*, 26(1). <http://go.galegroup.com/ps/i.do?id=GALE|A174972167&v=2.1&u=leicester&it=r&p=EAIM&sw=w&asid=07d8e79bb8f42665bb52cc5732948c88>

Ritholz, M. D., MacNeil, T., & Weinger, K. (2017a). Difficult conversations: adults with diabetes and the discussion of microvascular complications. *Diabetic Medicine*. <https://doi.org/10.1111/dme.13419>

Ritholz, M. D., MacNeil, T., & Weinger, K. (2017b). Difficult conversations: adults with diabetes and the discussion of microvascular complications. *Diabetic Medicine*, 34(10), 1447–1455. <https://doi.org/10.1111/dme.13419>

Romero-Aroca, P., Navarro-Gil, R., Valls-Mateu, A., Sagarra-Alamo, R., Moreno-Ribas, A., & Soler, N. (2017a). Differences in incidence of diabetic retinopathy between type 1 and 2 diabetes mellitus: a nine-year follow-up study. *British Journal of Ophthalmology*. <https://doi.org/10.1136/bjophthalmol-2016-310063>

Romero-Aroca, P., Navarro-Gil, R., Valls-Mateu, A., Sagarra-Alamo, R., Moreno-Ribas, A., & Soler, N. (2017b). Differences in incidence of diabetic retinopathy between type 1 and 2 diabetes mellitus: a nine-year follow-up study. *British Journal of Ophthalmology*. <https://doi.org/10.1136/bjophthalmol-2016-310063>

Romero-Aroca, P., Navarro-Gil, R., Valls-Mateu, A., Sagarra-Alamo, R., Moreno-Ribas, A., & Soler, N. (2017c). Differences in incidence of diabetic retinopathy between type 1 and 2 diabetes mellitus: a nine-year follow-up study. *British Journal of Ophthalmology*. <https://doi.org/10.1136/bjophthalmol-2016-310063>

Rosenberg, J. B., & Tsui, I. (2017). Screening for Diabetic Retinopathy. *New England Journal of Medicine*, 376(16), 1587–1588. <https://doi.org/10.1056/NEJMe1701820>

Saha, S. A., & Arora, R. R. (2010). Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus – A pooled meta-analysis of randomized placebo-controlled clinical trials. *International Journal of Cardiology*, 141(2), 157–166. <https://doi.org/10.1016/j.ijcard.2008.11.211>

- Santi, D., Granata, A. R. M., Guidi, A., Pignatti, E., Trenti, T., Roli, L., Bozic, R., Zaza, S., Pacchioni, C., Romano, S., Nofer, J. R., Rochira, V., Carani, C., & Simoni, M. (2016). Six months of daily treatment with vardenafil improves parameters of endothelial inflammation and of hypogonadism in male patients with type 2 diabetes and erectile dysfunction: a randomized, double-blind, prospective trial. *European Journal of Endocrinology*, 174(4), 513–522. <https://doi.org/10.1530/EJE-15-1100>
- Schrier, R. W., Estacio, R. O., & Jeffers, B. (1996). Appropriate Blood Pressure Control in NIDDM (ABCD) Trial. *Diabetologia*, 39(12), 1646–1654. <https://doi.org/10.1007/s001250050629>
- Scott, A. R. (2015). Management of hyperosmolar hyperglycaemic state in adults with diabetes. *Diabetic Medicine*, 32(6), 714–724. <https://doi.org/10.1111/dme.12757>
- Seidu, S., Achana, F. A., Gray, L. J., Davies, M. J., & Khunti, K. (2016). Effects of glucose-lowering and multifactorial interventions on cardiovascular and mortality outcomes: a meta-analysis of randomized control trials. *Diabetic Medicine*, 33(3), 280–289. <https://doi.org/10.1111/dme.12885>
- Soliman, E. Z., Backlund, J.-Y. C., Bebu, I., Orchard, T. J., Zinman, B., & Lachin, J. M. (2017). Electrocardiographic Abnormalities and Cardiovascular Disease Risk in Type 1 Diabetes: The Epidemiology of Diabetes Interventions and Complications (EDIC) Study. *Diabetes Care*, 40(6), 793–799. <https://doi.org/10.2337/dc16-2050>
- Solomon, S. D., Chew, E., Duh, E. J., Sobrin, L., Sun, J. K., VanderBeek, B. L., Wykoff, C. C., & Gardner, T. W. (2017a). Diabetic Retinopathy: A Position Statement by the American Diabetes Association. *Diabetes Care*, 40(3), 412–418. <https://doi.org/10.2337/dc16-2641>
- Solomon, S. D., Chew, E., Duh, E. J., Sobrin, L., Sun, J. K., VanderBeek, B. L., Wykoff, C. C., & Gardner, T. W. (2017b). Erratum. Diabetic Retinopathy: A Position Statement by the American Diabetes Association. *Diabetes Care* 2017;40:412–418. *Diabetes Care*. <https://doi.org/10.2337/dc17-er06e>
- Solomon, S. D., Chew, E., Duh, E. J., Sobrin, L., Sun, J. K., VanderBeek, B. L., Wykoff, C. C., & Gardner, T. W. (2017c). Erratum. Diabetic Retinopathy: A Position Statement by the American Diabetes Association. *Diabetes Care* 2017;40:412–418. *Diabetes Care*. <https://doi.org/10.2337/dc17-er06e>
- Solomon, S. D., Chew, E., Duh, E. J., Sobrin, L., Sun, J. K., VanderBeek, B. L., Wykoff, C. C., & Gardner, T. W. (2017d). Erratum. Diabetic Retinopathy: A Position Statement by the American Diabetes Association. *Diabetes Care* 2017;40:412–418. *Diabetes Care*, 40(6), 809.3-809. <https://doi.org/10.2337/dc17-er06e>
- Sultan, A., Perriard, F., Macioce, V., Mariano-Goulart, D., Boegner, C., Daures, J.-P., & Avignon, A. (2017a). Evolution of silent myocardial ischaemia prevalence and cardiovascular disease risk factor management in Type 2 diabetes over a 10-year period: an observational study. *Diabetic Medicine*. <https://doi.org/10.1111/dme.13364>
- Sultan, A., Perriard, F., Macioce, V., Mariano-Goulart, D., Boegner, C., Daures, J.-P., & Avignon, A. (2017b). Evolution of silent myocardial ischaemia prevalence and cardiovascular disease risk factor management in Type 2 diabetes over a 10-year period:

an observational study. *Diabetic Medicine*. <https://doi.org/10.1111/dme.13364>

The changing face of diabetes complications - ClinicalKey. (n.d.).

<https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858716300109>

The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus. (1993). *New England Journal of Medicine*, 329(14), 977–986. <https://doi.org/10.1056/NEJM199309303291401>

The evolution of diabetic ketoacidosis: An update of its etiology, pathogenesis and management - ClinicalKey. (n.d.).

<https://www-clinicalkey-com.ezproxy4.lib.le.ac.uk/#!/content/journal/1-s2.0-S0026049515003728>

The Handbook for Vascular Risk Assessment, Risk Reduction and Risk Management - NHS Health Check. (n.d.).

http://www.healthcheck.nhs.uk/news/the_handbook_for_vascular_risk_assessment_risk_reduction_and_risk_management/

Turnbull, F. M., Abraira, C., Anderson, R. J., Byington, R. P., Chalmers, J. P., Duckworth, W. C., Evans, G. W., Gerstein, H. C., Holman, R. R., Moritz, T. E., Neal, B. C., Ninomiya, T., Patel, A. A., Paul, S. K., Travert, F., & Woodward, M. (2009a). Intensive glucose control and macrovascular outcomes in type 2 diabetes. *Diabetologia*, 52(11), 2288–2298. <https://doi.org/10.1007/s00125-009-1470-0>

Turnbull, F. M., Abraira, C., Anderson, R. J., Byington, R. P., Chalmers, J. P., Duckworth, W. C., Evans, G. W., Gerstein, H. C., Holman, R. R., Moritz, T. E., Neal, B. C., Ninomiya, T., Patel, A. A., Paul, S. K., Travert, F., & Woodward, M. (2009b). Intensive glucose control and macrovascular outcomes in type 2 diabetes. *Diabetologia*, 52(11), 2288–2298. <https://doi.org/10.1007/s00125-009-1470-0>

Type 1 diabetes in adults: diagnosis and management | Guidance and guidelines | NICE. (n.d.). <https://www.nice.org.uk/guidance/ng17>

Type 2 diabetes in adults: management | Guidance and guidelines | NICE. (n.d.). <https://www.nice.org.uk/guidance/ng28>

UK Prospective Diabetes Study Group. (1998). Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. *BMJ: British Medical Journal*, 317(7160). <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC28659/>

Umpierrez, G., & Korytkowski, M. (2016a). Diabetic emergencies — ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia. *Nature Reviews Endocrinology*, 12(4), 222–232. <https://doi.org/10.1038/nrendo.2016.15>

Umpierrez, G., & Korytkowski, M. (2016b). Diabetic emergencies — ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia. *Nature Reviews Endocrinology*, 12(4), 222–232. <https://doi.org/10.1038/nrendo.2016.15>

Valencia, W. M., & Florez, H. (2017). How to prevent the microvascular complications of

type 2 diabetes beyond glucose control. *BMJ*. <https://doi.org/10.1136/bmj.i6505>

Wannamethee, S. G., Shaper, A. G., Whincup, P. H., Lennon, L., & Sattar, N. (2011). Impact of Diabetes on Cardiovascular Disease Risk and All-Cause Mortality in Older Men: influence of age at onset, diabetes duration and established and novel risk factors. *Archives of Internal Medicine*, 171(5). <https://doi.org/10.1001/archinternmed.2011.2>

Webb, D. R., Zaccardi, F., Davies, M. J., Griffin, S. J., Wareham, N. J., Simmons, R. K., Rutten, G. E., Sandbaek, A., Lauritzen, T., Borch-Johnsen, K., & Khunti, K. (2016). Cardiovascular risk factors and incident albuminuria in screen-detected type 2 diabetes. *Diabetes/Metabolism Research and Reviews*. <https://doi.org/10.1002/dmrr.2877>

Weber, M. A., Bakris, G. L., Jamerson, K., Weir, M., Kjeldsen, S. E., Devereux, R. B., Velazquez, E. J., Dahlöf, B., Kelly, R. Y., Hua, T. A., Hester, A., & Pitt, B. (2010). Cardiovascular Events During Differing Hypertension Therapies in Patients With Diabetes. *Journal of the American College of Cardiology*, 56(1), 77–85. <https://doi.org/10.1016/j.jacc.2010.02.046>

Whelton, P. K. (2005). Clinical Outcomes in Antihypertensive Treatment of Type 2 Diabetes, Impaired Fasting Glucose Concentration, and Normoglycemia. *Archives of Internal Medicine*, 165(12). <https://doi.org/10.1001/archinte.165.12.1401>

White, J., Swerdlow, D. I., Preiss, D., Fairhurst-Hunter, Z., Keating, B. J., Asselbergs, F. W., Sattar, N., Humphries, S. E., Hingorani, A. D., & Holmes, M. V. (2016). Association of Lipid Fractions With Risks for Coronary Artery Disease and Diabetes. *JAMA Cardiology*, 1(6). <https://doi.org/10.1001/jamacardio.2016.1884>

Wong, M. G., Perkovic, V., Chalmers, J., Woodward, M., Li, Q., Cooper, M. E., Hamet, P., Harrap, S., Heller, S., MacMahon, S., Mancia, G., Marre, M., Matthews, D., Neal, B., Poulter, N., Rodgers, A., Williams, B., & Zoungas, S. (2016a). Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON. *Diabetes Care*, 39(5), 694–700. <https://doi.org/10.2337/dc15-2322>

Wong, M. G., Perkovic, V., Chalmers, J., Woodward, M., Li, Q., Cooper, M. E., Hamet, P., Harrap, S., Heller, S., MacMahon, S., Mancia, G., Marre, M., Matthews, D., Neal, B., Poulter, N., Rodgers, A., Williams, B., & Zoungas, S. (2016b). Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON. *Diabetes Care*, 39(5), 694–700. <https://doi.org/10.2337/dc15-2322>

Yavuz, M., Ersen, A., Hartos, J., Schwarz, B., Garrett, A. G., Lavery, L. A., Wukich, D. K., & Adams, L. S. (2017). Plantar Shear Stress in Individuals With a History of Diabetic Foot Ulcer: An Emerging Predictive Marker for Foot Ulceration. *Diabetes Care*, 40(2), e14–e15. <https://doi.org/10.2337/dc16-2204>

Yudkin, J. S., Richter, B., & Gale, E. A. (2011). Intensified glucose control in type 2 diabetes—whose agenda? *The Lancet*, 377(9773), 1220–1222. [https://doi.org/10.1016/S0140-6736\(10\)61112-9](https://doi.org/10.1016/S0140-6736(10)61112-9)

Zaccardi, F., Webb, D. R., Davies, M. J., Dhalwani, N. N., Gray, L. J., Chatterjee, S., Housley, G., Shaw, D., Hatton, J. W., & Khunti, K. (2017). Predicting hospital stay, mortality and readmission in people admitted for hypoglycaemia: prognostic models derivation and

validation. *Diabetologia*. <https://doi.org/10.1007/s00125-017-4235-1>

Zaccardi, F., Webb, D. R., Davies, M. J., Dhalwani, N. N., Housley, G., Shaw, D., Hatton, J. W., & Khunti, K. (2017). Risk factors and outcome differences in hypoglycaemia-related hospital admissions: A case-control study in England. *Diabetes, Obesity and Metabolism*. <https://doi.org/10.1111/dom.12941>

Zhang, C.-Y., Sun, A.-J., Zhang, S.-N., Wu, C., Fu, M.-Q., Xia, G., Wang, K.-Q., Zou, Y.-Z., & Ge, J.-B. (2010). Effects of intensive glucose control on incidence of cardiovascular events in patients with type 2 diabetes: A meta-analysis. *Annals of Medicine*, 42(4), 305–315. <https://doi.org/10.3109/07853891003796752>

Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Inzucchi, S. E. (2015). Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. *New England Journal of Medicine*, 373(22), 2117–2128. <https://doi.org/10.1056/NEJMoa1504720>

Zoungas, S., Arima, H., Gerstein, H. C., Holman, R. R., Woodward, M., Reaven, P., Hayward, R. A., Craven, T., Coleman, R. L., & Chalmers, J. (2017). Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. *The Lancet Diabetes & Endocrinology*, 5(6), 431–437. [https://doi.org/10.1016/S2213-8587\(17\)30104-3](https://doi.org/10.1016/S2213-8587(17)30104-3)